Roman Camarda

Roman Camarda is a Principal at Novo Holdings, where responsibilities include leading investments in life sciences companies within an evergreen venture fund that allocates over $500 million annually. Prior to this role, Roman served as Vice President and Senior Analyst at Aquilo Capital Management, focusing on diligence and analysis in human therapeutics. Earlier experience includes a position as Lead Translational Scientist in Business Development at the Buck Institute for Research on Aging, where contributions were made to biotech start-up incubation and research agreements. Roman began a research-focused career as a Translational Postdoctoral Fellow, studying NAD metabolism in aging and breast cancer. Educational qualifications include a PhD in Biomedical Sciences from the University of California, San Francisco, and dual degrees (BS in Biochemistry and BFA in Photomedia) from the University of Washington.